Molecular and Cellular Biochemistry

, Volume 354, Issue 1–2, pp 263–273 | Cite as

Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy

  • Bing-xin Li
  • Yi-ting Tang
  • Wei Wang
  • Yan-yun Xie
  • Na-sui Wang
  • Qiong-jing Yuan
  • Fang-fang Zhang
  • Zhang-zhe Peng
  • Gao-yun Hu
  • Li-jian Tao
Article
First Online:
Received:
Accepted:

Abstract

Fluorofenidone (FD) is a novel pyridone agent with significant antifibrotic effects in vitro. The purpose of this study is to investigate the effects of FD on renal interstitial fibrosis in rats with obstructive nephropathy caused by unilateral ureteral obstruction (UUO). With pirfenidone (PD, 500 mg/kg/day) and enalapril (10 mg/kg/day) as the positive treatment controls, the rats in different experimental groups were administered with FD (500 mg/kg/day) from day 4 to day 14 after UUO. The tubulointerstitial injury, interstitial collagen deposition, and expression of type I and type III collagen, transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), α-smooth muscle actin (α-SMA), and tissue inhibitor of metalloproteinase-1 (TIMP-1) were assessed. FD treatment significantly attenuated the prominently increased scores of tubulointerstitial injury, interstitial collagen deposition, and protein expression of type I and type III collagen in ureter-obstructed kidneys, respectively. As compared with untreated rats, FD also significantly reduced the expression of α-SMA, TGF-β1, CTGF, PDGF, and inhibitor of TIMP-1 in the obstructed kidneys. Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy through its regulation on fibrogenic growth factors, tubular cell transdifferentiation, and extracellular matrix.

Keywords

Fluorofenidone Obstructive nephropathy Renal interstitial fibrosis Transforming growth factor-β1 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant No. 30873110), by the Key Project of Science and Technology from the Ministry of Education (No. 107133), by the Key Project of the Natural Science Foundation (No. 07-JJ3056) of Hunan Province to Dr. Li-jian Tao. The technical help of Ji-ying Chen, Xuan Zheng, Jiao Qin, Ling Wang, Ling-hao Wang, and Wang-bin Ning is gratefully acknowledged.

References

  1. 1.
    Yang J, Liu Y (2002) Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 13(1):96–107CrossRefPubMedGoogle Scholar
  2. 2.
    Klahr S, Morrissey J (2002) Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283(5):F861–F875PubMedGoogle Scholar
  3. 3.
    Tang WW, Feng L, Xia Y, Wilson CB (1994) Extracellular matrix accumulation in immune-mediated tubulointerstitial injury. Kidney Int 45(4):1077–1084CrossRefPubMedGoogle Scholar
  4. 4.
    Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H et al (2008) Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 82(3–4):210–217CrossRefPubMedGoogle Scholar
  5. 5.
    Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB (2007) Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2(5):906–913CrossRefPubMedGoogle Scholar
  6. 6.
    Di Sario A, Bendia E, Macarri G, Candelaresi C, Taffetani S, Marzioni M et al (2004) The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 36(11):744–751CrossRefPubMedGoogle Scholar
  7. 7.
    Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K et al (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171(9):1040–1047CrossRefPubMedGoogle Scholar
  8. 8.
    Cao W, He L, Liu W, Huang Z, Cheng Z (2006) Determination of AKF-PD in whole blood of rat by HPLC-UV. J Chromatogr B Analyt Technol Biomed Life Sci 833(2):257–259CrossRefPubMedGoogle Scholar
  9. 9.
    Tao LJ, Zhang J, Hu GY (2004) Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H)-pyridone on renal fibroblast in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 29(2):139–141PubMedGoogle Scholar
  10. 10.
    Wang L, Hu GY, Shen H, Peng ZZ, Ning WB, Tao LJ (2009) Fluorofenidone inhibits TGF-beta1 induced CTGF via MAPK pathways in mouse mesangial cells. Pharmazie 64(10):680–684PubMedGoogle Scholar
  11. 11.
    Peng ZZ, Hu GY, Shen H, Wang L, Ning WB, Xie YY et al (2009) Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology 14(6):565–572CrossRefPubMedGoogle Scholar
  12. 12.
    Ishidoya S, Morrissey J, McCracken R, Klahr S (1996) Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int 49(4):1110–1119CrossRefPubMedGoogle Scholar
  13. 13.
    Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8(2):199–207PubMedGoogle Scholar
  14. 14.
    Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD et al (2005) Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16(9):2702–2713CrossRefPubMedGoogle Scholar
  15. 15.
    Broekema M, Harmsen MC, van Luyn MJ, Koerts JA, Petersen AH, van Kooten TG et al (2007) Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 18(1):165–175CrossRefPubMedGoogle Scholar
  16. 16.
    Shen H, Huang G, Hadi M, Choy P, Zhang M, Minuk GY et al (2003) Transforming growth factor-beta1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 285(3):G539–G546PubMedGoogle Scholar
  17. 17.
    Winer J, Jung CK, Shackel I, Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270(1):41–49CrossRefPubMedGoogle Scholar
  18. 18.
    Shen H, Fan Y, Yang X, Burczynski FJ, Li P, Gong Y (2005) Increased expression of cystic fibrosis transmembrane conductance regulator in rat liver after common bile duct ligation. J Cell Physiol 203(3):599–603CrossRefPubMedGoogle Scholar
  19. 19.
    Boor P, Sebekova K, Ostendorf T, Floege J (2007) Treatment targets in renal fibrosis. Nephrol Dial Transplant 22(12):3391–3407CrossRefPubMedGoogle Scholar
  20. 20.
    Chatziantoniou C, Dussaule JC (2005) Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol 289(2):F227–F234CrossRefPubMedGoogle Scholar
  21. 21.
    Duymelinck C, Deng JT, Dauwe SE, De Broe ME, Verpooten GA (1998) Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int 54(3):804–818CrossRefPubMedGoogle Scholar
  22. 22.
    RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR et al (2009) Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 20(8):1765–1775CrossRefPubMedGoogle Scholar
  23. 23.
    Al-Bayati MA, Xie Y, Mohr FC, Margolin SB, Giri SN (2002) Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol 64(3):517–525CrossRefPubMedGoogle Scholar
  24. 24.
    Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K (1998) Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54(1):99–109CrossRefPubMedGoogle Scholar
  25. 25.
    Bottinger EP, Bitzer M (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13(10):2600–2610CrossRefPubMedGoogle Scholar
  26. 26.
    Phanish MK, Winn SK, Dockrell ME (2010) Connective tissue growth factor-(CTGF, CCN2)—a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 114(3):e83–e92CrossRefPubMedGoogle Scholar
  27. 27.
    Gupta S, Clarkson MR, Duggan J, Brady HR (2000) Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58(4):1389–1399CrossRefPubMedGoogle Scholar
  28. 28.
    Wang S, Denichilo M, Brubaker C, Hirschberg R (2001) Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 60(1):96–105CrossRefPubMedGoogle Scholar
  29. 29.
    Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K et al (2004) Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15(6):1430–1440CrossRefPubMedGoogle Scholar
  30. 30.
    Taneda S, Hudkins KL, Topouzis S, Gilbertson DG, Ophascharoensuk V, Truong L et al (2003) Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol 14(10):2544–2555CrossRefPubMedGoogle Scholar
  31. 31.
    Duymelinck C, Dauwe SE, De Greef KE, Ysebaert DK, Verpooten GA, De Broe ME (2000) TIMP-1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult male rat. Kidney Int 58(3):1186–1201CrossRefPubMedGoogle Scholar
  32. 32.
    Badid C, Vincent M, Fouque D, Laville M, Desmouliere A (2001) Myofibroblast: a prognostic marker and target cell in progressive renal disease. Ren Fail 23(3–4):543–549CrossRefPubMedGoogle Scholar
  33. 33.
    Kisseleva T, Brenner DA (2008) Mechanisms of fibrogenesis. Exp Biol Med 233(2):109–122CrossRefGoogle Scholar
  34. 34.
    Sharma K, Cook A, Smith M, Valancius C, Inscho EW (2005) TGF-beta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 288:F1069–F1077CrossRefPubMedGoogle Scholar
  35. 35.
    Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB et al (2001) Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14(6):453–460PubMedGoogle Scholar
  36. 36.
    Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S (1995) Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47(5):1285–1294CrossRefPubMedGoogle Scholar
  37. 37.
    Shihab FS, Bennett WM, Tanner AM, Andoh TF (1997) Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 52(3):660–673CrossRefPubMedGoogle Scholar
  38. 38.
    Finckenberg P, Lassila M, Inkinen K, Pere AK, Krogerus L, Lindgren L et al (2001) Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation 71(7):951–958CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Bing-xin Li
    • 1
  • Yi-ting Tang
    • 1
  • Wei Wang
    • 1
  • Yan-yun Xie
    • 1
  • Na-sui Wang
    • 1
  • Qiong-jing Yuan
    • 1
  • Fang-fang Zhang
    • 1
  • Zhang-zhe Peng
    • 1
  • Gao-yun Hu
    • 2
  • Li-jian Tao
    • 1
    • 3
  1. 1.Division of Nephrology, Department of Internal MedicineXiangya Hospital, Central South UniversityChangshaChina
  2. 2.Faculty of Pharmaceutical SciencesCentral South UniversityChangshaChina
  3. 3.State Key Laboratory of Medical Genetics of ChinaCentral South UniversityChangshaChina

Personalised recommendations